Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer

• Main Authors: Xumin Zhou (Author), Libin Zou (Author), Hangyu Liao (Author), Junqi Luo (Author), Taowei Yang (Author), Jun Wu (Author), Wenbin Chen (Author), Kaihui Wu (Author), Shengren Cen (Author), Daojun Lv (Author), Fangpeng Shu (Author), Yu Yang (Author), Chun Li (Author), Bingkun Li (Author), Xiangming Mao (Author)
• Format: Book
• Published: Elsevier, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Owing to incurable castration-resistant prostate cancer (CRPC) ultimately developing after treating with androgen deprivation therapy (ADT), it is vital to devise new therapeutic strategies to treat CRPC. Treatments that target programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD...